MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding metabolic syndrome?

Abstract

In 1980, there was the first description of patients with nonalcoholic steatohepatitis (NASH), most of whom were overweight and had type 2 diabetes. In the following years, there has been a growing appreciation that metabolic dysfunction underpins this liver disease, and metabolic dysfunction also contributes to the increased risk of extrahepatic complications, manifest in nonalcoholic fatty liver disease (NAFLD) as a multisystem disease. In 2020 & 2023, it was proposed that NAFLD should be renamed and reclassified as metabolic dysfunction-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), respectively. Despite subtle differences between MAFLD and MASLD, there is excellent congruence between NAFLD, MAFLD, and MASLD definitions, and affected patients usually meet the criteria for all. The following is a perspective of the authors’ views as to the challenges and advantages of the new fatty liver disease terminology and classification.

Keywords

Insulin resistance / metabolic syndrome / metabolic dysfunction-associated fatty liver disease / MAFLD / metabolic dysfunction-associated steatotic liver disease / MASLD / nonalcoholic fatty liver disease / NAFLD / cardiovascular disease / extrahepatic complications

References

[1] Ludwig J,McGill DB.Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.Mayo Clin Proc1980;55:434-8.

[2] Byrne CD.NAFLD: a multisystem disease.J Hepatol2015;62:S47-64

[3] Targher G,Byrne CD.Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach.Lancet Gastroenterol Hepatol2021;6:578-88

[4] Mantovani A,Bonora E.Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis.Diabetes Care2018;41:372-82

[5] Mantovani A,Petracca G.Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.Lancet Gastroenterol Hepatol2021;6:903-13

[6] Mantovani A,Beatrice G.Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.Gut2022;71:156-62

[7] Mantovani A,Csermely A.Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals.Gut2022;Online ahead of print:gutjnl-2022-327672

[8] Mantovani A,Beatrice G.Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.Gut2022;71:778-88

[9] Byrne CD.Banting memorial lecture 2022: 'Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime'.Diabet Med2022;39:e14912 PMCID:PMC9546361

[10] Reaven GM.Banting lecture 1988. Role of insulin resistance in human disease.Diabetes1988;37:1595-607

[11] DeFronzo RA.Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.Diabetes Care1991;14:173-94

[12] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).JAMA2001;285:2486-97

[13] Lakka HM,Lakka TA.The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.JAMA2002;288:2709-16

[14] Onat A,Başar O,Toprak S.Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels--a prospective and cross-sectional evaluation.Atherosclerosis2002;165:285-92

[15] Sattar N,Scherbakova O.Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland coronary prevention study.Circulation2003;108:414-9

[16] Alberti KG,Shaw J.IDF Epidemiology Task Force Consensus GroupThe metabolic syndrome--a new worldwide definition.Lancet2005;366:1059-62

[17] Grundy SM,Daniels SR.American Heart AssociationNational HeartLungand Blood InstituteDiagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement.Circulation2005;112:2735-52

[18] Guzder RN,Mullee MA.Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes.Diabetologia2006;49:49-55

[19] Alberti KG,Grundy SM.International Diabetes Federation Task Force on Epidemiology and PreventionHational HeartLungand Blood InstituteAmerican Heart AssociationWorld Heart FederationInternational Atherosclerosis SocietyInternational Association for the Study of ObesityHarmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity.Circulation2009;120:1640-5

[20] Austin MA,Vranizan KM.Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.Circulation1990;82:495-506

[21] Targher G,Byrne CD.NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment.Diabetes Metab2021;47:101215

[22] Sniderman AD,Glavinovic T.Apolipoprotein B particles and cardiovascular disease: a narrative review.JAMA Cardiol2019;4:1287-95 PMCID:PMC7369156

[23] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.J Hepatol2020;73:202-9

[24] Lazarus JV,Francque SM,Terrault NA.Reply: a multi-society delphi consensus statement on new fatty liver disease nomenclature.Hepatology2024;79:E93-4

[25] Matthews DR,Rudenski AS,Treacher DF.Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.Diabetologia1985;28:412-9

[26] Geloneze B,Geloneze SR,Ermetice MN.The threshold value for insulin resistance (HOMA-IR) in an admixtured population IR in the Brazilian Metabolic Syndrome Study.Diabetes Res Clin Pract2006;72:219-20

[27] Moura FA,Cintra RM.Validation of surrogate indexes of insulin sensitivity in acute phase of myocardial infarction based on euglycemic-hyperinsulinemic clamp.Am J Physiol Endocrinol Metab2014;306:E399-403

[28] Bonora E,Alberiche M.Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.Diabetes Care2000;23:57-63

[29] Stern SE,Ferrannini E,Bogardus C.Identification of individuals with insulin resistance using routine clinical measurements.Diabetes2005;54:333-9

[30] Trépo E.Update on NAFLD genetics: From new variants to the clinic.J Hepatol2020;72:1196-209

[31] Sung KC,Sung JW,Byrne CD.Metabolically healthy obese subjects are at risk of fatty liver but not of pre-clinical atherosclerosis.Nutr Metab Cardiovasc Dis2014;24:256-62

[32] Chang Y,Cho J.Metabolically healthy obesity and the development of nonalcoholic fatty liver disease.Am J Gastroenterol2016;111:1133-40

[33] Hagström H,Ekstedt M.99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical.J Hepatol2024;80:e76-7

[34] Harrison SA,Neff GW.Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.Nat Med2023;29:2919-28 PMCID:PMC10667098

[35] Harrison S,Guy C.A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis.N Engl J Med2024;390:497-509

[36] Mantovani A,Targher G.Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review.Lancet Gastroenterol Hepatol2022;7:367-78